StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) stock

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$4.95+0.72 (+17.02%)

Close on Nov 18, 2026Market cap $186.79MP/E –Yield –

AN2 Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for AN2 Therapeutics

AN2 Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More AN2 Therapeutics figures

See a number that looks wrong?